China Cord Blood Corporation Announces Results of 2012 Annual
General Meeting
HONG KONG, Dec. 20, 2012 /PRNewswire-FirstCall/ -- China
Cord Blood Corporation (NYSE: CO) ("CCBC" or the "Company"),
the first and largest cord blood banking operator in China, today announced the results of its 2012
Annual General Meeting, which was held on December 19, 2012, in Hong Kong.
At the Annual General Meeting, shareholders
- Ratified the appointment of KPMG as the independent
auditor of the Company for the financial year ending March 31, 2013, and authorized any duly formed
committee of the directors to fix the remuneration of the auditors;
and
- Elected Mr. Yuen Kam, Mr. Julian
J. Wolhardt and Ms. Jennifer J.
Weng to serve on the Board of Directors until the 2015
Annual General Meeting of the Company or until their respective
successors are duly appointed and qualified, and Mr. Yuen Kam will
be the chairman of the board of directors; and
- Passed a special resolution to amend the articles of
association of the Company to change the threshold required to
approve future special resolutions from 75% of the votes cast to 66
2/3%, and authorized the directors to make all necessary filings in
respect of the amendments to the article of association.
About China Cord Blood Corporation
China Cord Blood Corporation is the first and largest cord blood
banking operator in China in terms
of geographical coverage and the only cord blood banking operator
with multiple licenses. Under current PRC government regulations,
only one licensed cord blood banking operator is permitted to
operate in each licensed region and only seven licenses have been
authorized as of today. China Cord Blood Corporation provides
cord blood collection, laboratory testing, hematopoietic stem cell
processing, and stem cell storage services. For more
information, please visit our website at
http://www.chinacordbloodcorp.com.
Safe Harbor Statement
This press release contains forward-looking statements as
defined by the Private Securities Litigation Reform Act of 1995.
Forward-looking statements include statements concerning plans,
objectives, goals, strategies, future events, performance and
results of operations, and underlying assumptions and other
statements that are other than statements of historical facts.
These statements are subject to uncertainties and risks including,
but not limited to, product and service demand and acceptance,
changes in technology, economic conditions, the impact of
competition and pricing, government regulation, and other risks
contained in statements filed from time to time with the U.S.
Securities and Exchange Commission. All such forward-looking
statements, whether written or oral, and whether made by or on
behalf of the Company, are expressly qualified by the cautionary
statements and any other cautionary statements which may accompany
the forward-looking statements. In addition, the Company disclaims
any obligation to update any forward-looking statements to reflect
events or circumstances after the date hereof.
For more information, please contact:
China Cord Blood Corporation
Investor Relations Department
Tel: (+852) 3605-8180
Email: ir@chinacordbloodcorp.com
ICR, Inc.
Mr. Rob Koepp
Tel: (+86) 10-6583-7516 (China) or
(646) 405-5185 (U.S.)
Email: robert.koepp@icrinc.com
SOURCE China Cord Blood Corporation